Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels

Journal of Oncology Practice

Volumn 11, Issue 3, 2015, Pages 252-258

  Shanafelt, Tait D ^a   Borah, Bijan J ^b   Finnes, Heidi D ^b   Chaffee, Kari G ^b   Ding, Wei ^b   Leis, Jose F ^b   Chanan Khan, Asher A ^b   Parikh, Sameer A ^b   Slager, Susan L ^b   Kay, Neil E ^b   Call, Tim G ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; IBRUTINIB; IDELALISIB; METHYLPREDNISOLONE; OBINUTUZUMAB; OFATUMUMAB; PENTOSTATIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; DRUG APPROVAL; DRUG COST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; REGISTER; SALVAGE THERAPY; UNITED STATES; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MINNESOTA; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH EXPENDITURES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MEDICARE PART D; MINNESOTA; MODELS, ECONOMIC; PROTEIN KINASE INHIBITORS; PURINES; PYRAZOLES; PYRIMIDINES; QUINAZOLINONES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84929670840     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2014.002469     Document Type: Article

References (58)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62:10-29, 2012
2. Shanafelt TD: Predicting clinical outcome in CLL: How and why. Hematology Am Soc Hematol Educ Program 2009:421-429, 2009
3. Dighiero G, Maloum K, Desablens B, et al: Cholorambucil in indolent chronic lymphocytic leukemia: French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 338:1506-1514, 1998
4. Call T, Phyilky R, Noël P, et al: Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clin Proc 69:323-328, 1994
5. Goede V, Fischer K, Busch R, et al: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370:1101-1110, 2014
6. Rai K, Peterson B, Appelbaum F, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757, 2000
7. Eichhorst BF, Busch R, Stilgenbauer S, et al: First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 114:3382-3391, 2009
8. Hallek M, Fischer K, Fingerle-Rowson G, et al: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 376:1164-1174, 2010
9. Goede V, Fischer K, Hallek M: Chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 370:2348-2349, 2014
10. Fischer K, Cramer P, Busch R, et al: Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 30:3209-3216, 2012
11. Tam CS, O'Brien S, Wierda W, et al: Long term results of the fludarabine, cyclophosphamide and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112:975-980, 2008
12. Stilgenbauer S, Schnaiter A, Paschka P, et al: Gene mutations and treatment outcome in chronic lymphocytic leukemia: Results from the CLL8 trial. Blood 123:3247-3254, 2014
13. Shanafelt TD, Gunderson H, Call TG: Chronic lymphocytic leukemia-the price of progress. Oncologist 15:601-602, 2010
14. O'Brien S, Furman RR, Coutre SE, et al: Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b/2 trial. Lancet Oncol 15:48-58, 2014
15. Farooqui M, Aue G, Valdez J, et al: Single agent ibrutinib (PCI-32765) achieves equally good and durable responses in chronic lymphocytic leukemia (CLL) patients with and without deletion 17p. Blood 122, 2013 (abstr 673)
16. O'Brien SM, Furman R, Coutre SE, et al: Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease. J Clin Oncol 32:447s, 2014(suppl 15s; abstr 7014)
17. Cheson BD, Byrd JC, Rai KR, et al: Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 30:2820-2822, 2012
18. Byrd JC, Furman RR, Coutre SE, et al: Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32-42, 2013
19. Byrd JC, Brown JR, O'Brien S, et al: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371:213-223, 2014
20. Furman RR, Sharman JP, Coutre SE, et al: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370:997-1007, 2014
21. Coutre S, Furman R, Sharman JP, et al: Second interim analysis of a phase 3 study evaluating idelalisib and rituxiamb for relapsed CLL. J Clin Oncol 32:447s, 2014(suppl 15s; abstr 7012)
22. Cheson BD, Bennett JM, Rai KR, et al: Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 29:152-163, 1988
23. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
24. Hallek M, Cheson BD, Catovsky D, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group 1996 guidelines. Blood 111:5446-5456, 2008
25. St Sauver JL, Grossardt BR, Yawn BP, et al: Use of a medical records linkage system to enumerate a dynamic population over time: The Rochester epidemiology project. Am J Epidemiol 173:1059-1068, 2011
26. Knauf WU, Lissichkov T, Aldaoud A, et al: Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:4378-4384, 2009
27. Hillmen P, Skotnicki AB, Robak T, et al: Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616-5623, 2007
28. Keating M, O'brien S, Albitar M, et al: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088, 2005
29. Wierda WG, Kipps TJ, Mayer J, et al: Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28:1749-1755, 2010
30. Hallek M: Signaling the end of chronic lymphocytic leukemia: New frontline treatment strategies. Hematology Am Soc Hematol Educ Program 2013:138-150, 2013
31. Eichhorst B, Fink A, Busch R, et al: Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a planned interim analysis of the CLL10 trial, an international, randomized study of the German CLL Study Group (GCLLSG). Blood 122, 2013 (abstr 526)
32. Fischer K, Cramer P, Busch R, et al: Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 29:3559-3566, 2011
33. Cramer P, Fink AM, Busch R, et al: Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group. Leuk Lymphoma 54:1821-1822, 2013
34. Byrd JC, Peterson BL, Morrison VA, et al: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6-14, 2003
35. Gerrie AS, Toze CL, Ramadan KM, et al: Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: Population-based experience matches clinical trials. Leuk Lymphoma 53:77-82, 2012
36. Wierda W, O'Brien S, Wen S, et al: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23:4070-4078, 2005
37. Robak T, Dmoszynska A, Solal-Céligny P, et al: Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 28:1756-1765, 2010
38. Kay NE, Geyer SM, Call TG, et al: Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109:405-411, 2007
39. Lamanna N, Kalaycio M, Maslak P, et al: Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 24:1575-1581, 2006
40. National Comprehensive Cancer Network: NCCN Guidelines Non-Hodgkin's Lymphomas. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
41. Hallek M: Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol 88:803-816, 2013
42. Pagel JM, Coutre S, Furman R, et al: Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed chronic lymphocytic leukemia (CLL). Presented at the Annual Meeting of the Society of Hematology and Oncology, Houston, TX, September 17-20, 2014 (abstr 93)
43. US National Institutes of Health: ClinicalTrials.gov. https://clinicaltrials.gov
44. Cramer P, Fink AM, Busch R, et al: Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group. Leuk Lymphoma 54:1821-1822, 2013
45. Henry J. Kaiser Family Foundation: The Medicare Part D Prescription Drug Benefit. https://kaiserfamilyfoundation. files.wordpress.com/2013/11/7044-14-medicare-part-d-fact-sheet.pdf
46. Experts in Chronic Myeloid Leukemia: The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood 121:4439-4442, 2013
47. Wierda WG, Seymour JF, Roberts AW, et al: A phase 2 open-label study of the efficacy of ABT-199 (GDC-199) in patients wiht relapsd or refractory (R/R) chronic lymphocytic leukemia (CLL) harboring 17p deletion. J Clin Oncol 32:474s, 2014(suppl 15s; abstr TPS7121)
48. Dusetzina SB, Winn AN, Abel GA, et al: Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32:306-311, 2014
49. Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 353:487-497, 2005
50. Stuart B, Zacker C: Who bears the burden of Medicaid drug copayment policies? Health Aff (Millwood) 18:201-212, 1999
51. Noens L, Van Lierde MA, De Bock R, et al: Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood 113:5401-5411, 2009
52. Zafar SY, Peppercorn JM, Schrag D, et al: The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 18:381-390, 2013
53. Schrag D: The price tag on progress: Chemotherapy for colorectal cancer. N Engl J Med 351:317-319, 2004
54. Fojo T, Grady C: How much is life worth: Cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 101:1044-1048, 2009
55. Ruiz-Argüelles GJ, Tarin-Arzaga LC, Gonzalez-Carrillo ML, et al: Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? Bone Marrow Transplant 42:23-28, 2008
56. Kantarjian HM, Fojo T, Mathisen M, et al: Cancer drugs in the United States: Justum pretium-The just price. J Clin Oncol 31:3600-3604, 2013
57. US Government Accountability Office: Medicare Part D: Spending, Beneficiary Cost Sharing, and Cost-Containment Efforts for High-Cost Drugs Eligible for a Specialty Tier. http://www.gao.gov/new.items/d10242.pdf
58. Kantarjian H, Steensma D: Relevance of the Hippocratic oath in the 21st century. http://www.ascopost.com/issues/october-15,-2014/relevance-of-thehippocratic-oath-in-the-21st-century.aspx